ReviewEye (London, England)2026
Management of uveitic and chorioretinal conditions in pregnancy.
Review in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on: 'Management of uveitic and chorioretinal conditions in pregnancy'.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During pregnancy, women may develop de novo sight-threatening chorioretinal diseases or experience exacerbations of these conditions. Examples include macular neovascularisation, diabetic macular oedema, and posterior uveitis. Ophthalmologists may not necessarily recommend the standard treatment for these disorders when they arise in pregnant women due to a lack of evidence regarding safety and potential risks of teratogenicity and fetotoxicity, and a lack of experience with managing this patient population. However, withholding treatment may lead to irreversible maternal vision loss. In this review, we discuss therapies that may need to be considered in these conditions, including steroids, intraocular pressure-lowering treatment for steroid-induced glaucoma, systemic immunosuppressants, and intravitreal anti-vascular endothelial growth factor agents. We discuss the evidence base behind these treatments in terms of safety in pregnancy, bringing in the obstetric perspective. We also discuss common misconceptions surrounding different modes of delivery in pregnant women with chorioretinal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.